TY - JOUR
TI - The efficacy of Natalizumab versus Fingolimod for patients with relapsing-remitting multiple sclerosis: A systematic review, indirect evidence from randomized placebo-controlled trials and meta-analysis of observational head-to-head trials
AU - Tsivgoulis, G.
AU - Katsanos, A.H.
AU - Mavridis, D.
AU - Grigoriadis, N.
AU - Dardiotis, E.
AU - Heliopoulos, I.
AU - Papathanasopoulos, P.
AU - Karapanayiotides, T.
AU - Kilidireas, C.
AU - Hadjigeorgiou, G.M.
AU - Voumvourakis, K.
AU - Gravanis, A.
AU - Papadimitriou, A.
AU - Rompos, A.
AU - Mouzaki, A.
AU - Kylintireas, C.
AU - Voumvourakis, C.
AU - Karagogeos, D.
AU - Hadjigeorgiou, G.
AU - Kollias, G.
AU - Helliopoulos, I.
AU - Probert, L.
AU - Ioannidis, P.
AU - Pelidou, S.-E.
AU - Tzartos, S.
AU - Karapanagiotides, T.
AU - Panoutsakopoulou, V.
AU - HELANI (Hellenic Academy of Neuroimmunology)
JO - PLOS ONE
PY - 2016
VL - 11
TODO - 9
SP - null
PB - Public Library of Science
SN - null
TODO - 10.1371/journal.pone.0163296
TODO - fingolimod;  natalizumab;  placebo, Article;  clinical effectiveness;  clinical evaluation;  disability;  disease association;  disease course;  drug efficacy;  human;  meta analysis;  multiple sclerosis;  observational study;  randomized controlled trial (topic);  relapse;  systematic review;  treatment outcome;  treatment planning
TODO - Background: Although Fingolimod (FGD) and Natalizumab (NTZ) appear to be effective in relapsing-remitting multiple sclerosis (RRMS), they have never been directly compared in a randomized clinical trial (RCT). Methods and Findings: We evaluated the comparative efficacy of FGD vs. NTZ using a meta-analytical approach. Data from placebo-controlled RCTs was used for indirect comparisons and observational data was utilized for head-to-head comparisons. We identified 3 RCTs (2498 patients) and 5 observational studies (2576 patients). NTZ was associated with a greater reduction in the 2-year annualized relapse rate (ARR; SMDindirect = -0.24;95% CI: from -0.44 to -0.04; p = 0.005) and with the probability of no disease activity at 2 years (ORindirect:1.82, 95% CI: from 1.05 to 3.15) compared to FGD, while no differences between the two therapies were found in the proportion of patients who remained relapse-free (ORindirect= 1.20;95% CI: from 0.84 to 1.71) and those with disability progression (ORindirect = 0.76;95% CI: from 0.48 to 1.21) at 2 years. In the analysis of observational data, we found no significant differences between NTZ and FGD in the 2-year ARR (SMD = -0.05; 95% CI: from -0.26 to 0.16), and 2-year disability progression (OR:1.08;95% CI: from 0.77 to 1.52). However, NTZ-treated patients were more likely to remain relapse-free at 2-years compared to FGD (OR: 2.19;95% CI: from 1.15 to 4.18; p = z0.020). Conclusions: Indirect analyses of RCT data and head-to-head comparisons of observational findings indicate that NTZ may be more effective than FGD in terms of disease activity reduction in patients with RRMS. However, head-to-head RCTs are required to independently confirm this preliminary observation. © 2016 Tsivgoulis et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ER -